This hypothesis is in good agreement with our data indicating that Endocan has a similar but not identical effect as PDGF-BB– one of the cognate ligands of PDGFRA, suggesting that Endocan may activate other yet unknown receptors in GBM. The gene discussed is ESM1; the disease is glioblastoma.